Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Inflammation, non-endothelial dependent coronary microvascular function and diastolic function-Are they linked?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lipidomics of human adipose tissue reveals diversity between body areas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The epidemiology of inflammatory bowel disease: East meets West

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Johan Burisch
  • Wolfgang Eigner
  • Stefan Schreiber
  • Daniel Aletaha
  • Wolfgang Weninger
  • Michael Trauner
  • Walter Reinisch
  • Neeraj Narula
Vis graf over relationer

OBJECTIVE: Cases of inflammatory bowel disease (IBD) during treatment with interleukin (IL)-17 antagonists have been reported from trials in psoriasis, psoriatic arthritis, and ankylosing spondylitis. The aim of this study was to assess the overall risk for development of IBD due to IL-17 inhibition.

DESIGN: Systematic review and meta-analysis of studies conducted 2010-2018 of treatment with IL-17 antagonists in patients with psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. We compared risk of IBD development in anti-IL-17 treated patients compared to placebo treatments. We also computed incident rates of IBD overall. A 'worst case scenario' defining subjects ambiguous for prevalent versus incident cases for the latter was also applied.

RESULTS: Sixty-six studies of 14,390 patients exposed to induction and 19,380 patients exposed to induction and/or maintenance treatment were included. During induction, 11 incident cases of IBD were reported, whereas 33 cases were diagnosed during the entire treatment period. There was no difference in the pooled risk of new-onset IBD during induction studies for both the best-case [risk difference (RD) 0.0001 (95% CI: -0.0011, 0.0013)] and worst-case scenario [RD 0.0008 (95% CI: -0.0005, 0.0022)]. The risk of IBD was not different from placebo when including data from maintenance and long-term extension studies [RD 0.0007 (95% CI: -0.0023, 0.0036) and RD 0.0022 (95% CI: -0.0010, 0.0055), respectively].

CONCLUSIONS: The risk for development of IBD in patients treated with IL-17 antagonists is not elevated. Prospective surveillance of patients treated with IL-17 antagonists with symptom and biomarker assessments is warranted to assess for onset of IBD in these patients.

OriginalsprogEngelsk
Artikelnummere0233781
TidsskriftPLoS One
Vol/bind15
Udgave nummer5
ISSN1932-6203
DOI
StatusUdgivet - 27 maj 2020

ID: 59971936